X0407 4 2023-05-01 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001643921 Bhatia Sangeeta N. C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 1 0 0 0 1 Common Stock 2023-05-01 4 A 0 1168 0.00 A 5208 D Common Stock 2023-05-02 4 S 0 62 345.93 D 5146 D Common Stock 2023-05-02 4 S 0 172 346.69 D 4974 D Common Stock 2023-05-02 4 S 0 120 348.16 D 4854 D Common Stock 2023-05-02 4 S 0 163 349.82 D 4691 D Common Stock 2023-05-02 4 S 0 63 351.20 D 4628 D Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date. Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1, which was entered into on 05/17/2022. Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $345.93 (range $345.20 to $346.12). Open market sales reported on this line occurred at a weighted average price of $346.69 (range $346.31 to $347.03). Open market sales reported on this line occurred at a weighted average price of $348.16 (range $347.91 to $348.64). Open market sales reported on this line occurred at a weighted average price of $349.82 (range $349.17 to $350.08). Open market sales reported on this line occurred at a weighted average price of $351.20 (range $350.92 to $351.48). /s/ Christiana Stevenson, Attorney-in-Fact 2023-05-03